Subject Index

Recent PCC Articles on Subject Index

JCP
Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorders
Original Research ▶ Video

Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorders

September 16, 2026

This analysis suggests that maintenance doses of paliperidone palmitate 351 mg at different dosing intervals may offer additional treatment options for clinical use.
, , , et al
Switching From Oral Atypical Antipsychotics to Xanomeline-Trospium in Schizophrenia

Switching From Oral Atypical Antipsychotics to Xanomeline-Trospium in Schizophrenia

September 15, 2026

A Clinical Pearl on switching patients from oral atypical antipsychotics to xanomeline-trospium: 2- vs 4-week taper data and panel guidance.
PCC
The Aftermath of Risking Life and Limb
Rounds in the General Hospital

The Aftermath of Risking Life and Limb

September 15, 2026

Traumatic injuries (often the result of impulsive and thoughtless behaviors) are potent drivers of disability, disfigurement, PTSD, TBIs, mortality, and high health care costs.
, , , et al

Featured Subject Index Research

JCP
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress

September 14, 2026

Adjunctive lumateperone 42 mg significantly improved depression and anxiety symptoms in patients with MDD with inadequate antidepressant response and anxious distress
, , , et al
JCP
Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Care: Data From EPINET
Original Research

Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Care: Data From EPINET

September 14, 2026

Data from the EPINET project reveal wide variation in the prescription of LAIs and clozapine across first-episode specialty care clinics.
, , , et al
PCC
Lorazepam in Chronic Catatonia Reversal
Case Report

Lorazepam in Chronic Catatonia Reversal

September 10, 2026

This report describes chronic organic catatonia following cerebral malaria in a 17-year-old male, who experienced a marked response to lorazepam.
, ,

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe